Volume 24, Number 9—September 2018
Research Letter
Fluconazole-Resistant Candida parapsilosis Bloodstream Isolates with Y132F Mutation in ERG11 Gene, South Korea
Table
Microsatellite
genotypes† |
Hospital |
No. isolates |
MICs, mg/L‡ | Amino acid substitutions§ | Isolation year (no. patients) |
|||||
---|---|---|---|---|---|---|---|---|---|---|
FLC |
VRC |
Erg11p |
Mrr1p |
Tac1p |
Upc2p |
|||||
Fluconazole-resistant with Y132F in Erg11p, n = 30 isolates | ||||||||||
M1 | A | 8 | 8–32 | 0.25–0.5 | Y132F | K177N | 2006 (1), 2009 (1), 2010 (2), 2011 (2), 2012 (1), 2013 (1) | |||
B | 3 | 16–32 | 0.5 | Y132F | K177N | 2012 (2), 2013 (1) | ||||
M2 | A | 10 | 8–32 | 0.125–0.5 | Y132F | K177N | 2012 (1), 2016 (9) | |||
M3 | A | 3 | 8–16 | 0.25 | Y132F | K177N, Q1053* | 2007 (1), 2011 (1), 2012 (1) | |||
M4 | A | 2 | 8–>64 | 0.5–4 | Y132F | K177N | 2013 (1), 2016 (1) | |||
M5 | A | 1 | 32 | 0.25 | Y132F | K177N | 2012 (1) | |||
M6 | A | 1 | 8 | 0.5 | Y132F | K177N | 2013 (1) | |||
M7 | A | 1 | 8 | 0.25 | Y132F | K177N | 2016 (1) | |||
M8 |
C |
1 |
64 |
2 |
Y132F |
2016 (1) |
||||
Other fluconazole-resistant, n = 17 isolates | ||||||||||
M9 | D | 2 | >64 | 1 | G583R | 2007 (1), 2009 (1) | ||||
M10 | E | 1 | 16 | 0.5 | R398I | L877P | 2005 (1) | |||
M11 | A | 1 | 8 | 0.25 | 2006 (1) | |||||
M12 | E | 1 | 8 | 0.25 | R398I | L877P | 2011 (1) | |||
M13 | F | 1 | 16 | 0.06 | R398I | L877P | 2011 (1) | |||
M14 | E | 1 | 8 | 0.125 | R398I | L877P | 2012 (1) | |||
M15 | G | 1 | 8 | 0.125 | R398I | L877P | 2012 (1) | |||
M16 | G | 1 | 8 | 0.06 | R398I | L877P | 2012 (1) | |||
M17 | E | 1 | 8 | 0.125 | N900D | 2012 (1) | ||||
M18 | C | 1 | 8 | 0.125 | R398I | P250S | L877P | 2012 (1) | ||
M19 | C | 1 | 8 | 0.25 | R398I | S1081P | L877P | 2012 (1) | ||
M20 | D | 1 | 8 | 0.125 | R398I | D394N | 2012 (1) | |||
M21 | E | 1 | 32 | 0.5 | R398I | P295R | L877P | 2015 (1) | ||
M22 | E | 1 | 16 | 0.125 | R398I | 2015 (1) | ||||
M23 | H | 1 | 32 | 0.125 | K128N | W872C | 2015 (1) | |||
M24 |
E |
1 |
16 |
0.25 |
G927D |
2016 (1) |
||||
Fluconazole-susceptible controls | ||||||||||
M3 | A | 1 | 1 | 0.03 | K177N, Q1053* | 2010 (1) | ||||
M25 | C | 2 | 0.5 | 0.03 | R398I | 2012 (2) | ||||
M26 | F | 2 | 0.5 | 0.03–0.06 | R208G | 2012 (1), 2013 (1) | ||||
M27 | A | 1 | 2 | 0.06 | 2010 (1) | |||||
M28 | A | 1 | 0.5 | 0.03 | K177N, Q1053* | 2011 (1) | ||||
M29 | A | 1 | 1 | 0.06 | L877P | 2011 (1) | ||||
M30 | A | 1 | 1 | 0.03 | R208G | 2012 (1) | ||||
M31 | A | 1 | 0.5 | 0.03 | R208G | 2012 (1) | ||||
M32 | E | 1 | 2 | 0.03 | 2012 (1) | |||||
M33 | G | 1 | 0.5 | 0.03 | R208G | 2012 (1) | ||||
M34 | G | 1 | 0.5 | 0.03 | 2012 (1) | |||||
M35 | A | 1 | 0.5 | 0.03 | R208G | 2013 (1) | ||||
M36 | A | 1 | 1 | 0.06 | R398I | D394N | 2013 (1) | |||
M37 | A | 1 | 0.5 | 0.03 | R398I | 2013 (1) | ||||
M38 | D | 1 | 0.5 | 0.06 | R398I | 2014 (1) | ||||
M39 | D | 1 | 0.5 | 0.06 | R208G | 2014 (1) | ||||
M40 | E | 1 | 0.5 | 0.03 | R208G | 2015 (1) | ||||
M41 | A | 1 | 1 | 0.03 | R398I | L877P | 2015 (1) |
*CLSI, Clinical and Laboratory Standards Institute; FLC, fluconazole; VRC, voriconazole.
†For microsatellite typing, each strain was characterized by a genotype resulting from combination of the sizes of the 4 markers (CP1, CP4, CP6, and B). See the Technical Appendix Figure for results of microsatellite genotyping presented as an UPGMA tree.
‡Antifungal MICs were determined by the CLSI M27–A3 broth microdilution method (7). The fluconazole MICs of 30 Y132F isolates determined by Etest were ≥8 mg/L. All 67 isolates tested were susceptible to amphotericin B (MIC 0.25–1 mg/L) and micafungin (MIC 0.25–2 mg/L) according to the CLSI method.
§All were homozygote alleles except for 6 heterozygote alleles (Q1053,* G583R, P250S, P295R, W872C, and G927D) in Mrr1p.
References
- Pfaller MA, Jones RN, Doern GV, Sader HS, Messer SA, Houston A, et al.; The SENTRY Participant Group. Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998. Antimicrob Agents Chemother. 2000;44:747–51. DOIPubMedGoogle Scholar
- Souza AC, Fuchs BB, Pinhati HM, Siqueira RA, Hagen F, Meis JF, et al. Candida parapsilosis resistance to fluconazole: molecular mechanisms and in vivo impact in infected Galleria mellonella larvae. Antimicrob Agents Chemother. 2015;59:6581–7. DOIPubMedGoogle Scholar
- Grossman NT, Pham CD, Cleveland AA, Lockhart SR. Molecular mechanisms of fluconazole resistance in Candida parapsilosis isolates from a U.S. surveillance system. Antimicrob Agents Chemother. 2015;59:1030–7. DOIPubMedGoogle Scholar
- Berkow EL, Manigaba K, Parker JE, Barker KS, Kelly SL, Rogers PD. Multidrug transporters and alterations in sterol biosynthesis contribute to azole antifungal resistance in Candida parapsilosis. Antimicrob Agents Chemother. 2015;59:5942–50. DOIPubMedGoogle Scholar
- Asadzadeh M, Ahmad S, Al-Sweih N, Khan Z. Epidemiology and molecular basis of resistance to fluconazole among clinical Candida parapsilosis isolates in Kuwait. Microb Drug Resist. 2017;23:966–72. DOIPubMedGoogle Scholar
- Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts—third edition: approved standard (M27–A3). Wayne (PA): The Institute; 2008.
- Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts: fourth informational supplement (M27–S4). Wayne (PA): The Institute; 2012.
- Lockhart SR, Etienne KA, Vallabhaneni S, Farooqi J, Chowdhary A, Govender NP, et al. Simultaneous emergence of multidrug-resistant Candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses. Clin Infect Dis. 2017;64:134–40. DOIPubMedGoogle Scholar
- Welsh RM, Bentz ML, Shams A, Houston H, Lyons A, Rose LJ, et al. Survival, persistence, and isolation of the emerging multidrug-resistant pathogenic yeast Candida auris on a plastic health care surface. J Clin Microbiol. 2017;55:2996–3005. DOIPubMedGoogle Scholar
1These authors contributed equally to this article.